Harbor Advisors LLC Purchases Shares of 2,000 BioNTech SE (NASDAQ:BNTX)

Harbor Advisors LLC acquired a new stake in BioNTech SE (NASDAQ:BNTX) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 2,000 shares of the company’s stock, valued at approximately $238,000.

Other institutional investors also recently made changes to their positions in the company. CANADA LIFE ASSURANCE Co boosted its holdings in shares of BioNTech by 79.6% in the first quarter. CANADA LIFE ASSURANCE Co now owns 3,426 shares of the company’s stock valued at $316,000 after acquiring an additional 1,518 shares in the last quarter. Tidal Investments LLC bought a new position in BioNTech in the first quarter valued at approximately $703,000. EverSource Wealth Advisors LLC lifted its position in shares of BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after purchasing an additional 252 shares during the period. GAMMA Investing LLC grew its stake in shares of BioNTech by 86.9% in the 2nd quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock worth $41,000 after acquiring an additional 238 shares in the last quarter. Finally, Granite Bay Wealth Management LLC bought a new stake in shares of BioNTech during the 2nd quarter valued at about $1,483,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Price Performance

Shares of BNTX opened at $117.20 on Tuesday. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49. The stock’s 50-day moving average price is $113.81 and its two-hundred day moving average price is $98.77. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating the consensus estimate of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. During the same quarter last year, the business earned $0.73 earnings per share. The firm’s revenue was up 38.9% on a year-over-year basis. As a group, research analysts expect that BioNTech SE will post -3.72 EPS for the current year.

Analyst Ratings Changes

BNTX has been the topic of several research reports. Evercore ISI upgraded BioNTech from an “in-line” rating to an “outperform” rating and raised their target price for the company from $110.00 to $125.00 in a research report on Tuesday, November 19th. UBS Group boosted their price objective on BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 18th. Morgan Stanley upgraded BioNTech from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $93.00 to $145.00 in a research report on Tuesday, September 24th. Berenberg Bank began coverage on BioNTech in a report on Tuesday, November 19th. They issued a “buy” rating and a $130.00 price target for the company. Finally, Jefferies Financial Group upgraded BioNTech from a “hold” rating to a “buy” rating and raised their price objective for the stock from $96.00 to $150.00 in a research note on Tuesday, September 17th. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $138.67.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.